Rubicon Research has scheduled its 27th Annual General Meeting (AGM) for August 26, 2026, to seek shareholder approval for a proposed final dividend of ₹1.50 per equity share and the fast-track merger of its wholly-owned subsidiary, KIA Health Tech Private Limited. The meeting, held via video conferencing, also aims to ratify a new employee stock option plan (ESOP 2026) and approve remuneration for independent directors. Investors must submit tax documentation by August 10, 2026, to ensure accurate Tax Deduction at Source (TDS) on the dividend, which is subject to approval at the AGM.

The proposed dividend of ₹1.50 per share represents a significant increase from the previous year’s payout of ₹0.02 per share. The Board of Directors recommended this distribution during its meeting on May 29, 2026, citing strong financial performance in FY26. The total dividend payout is estimated at approximately ₹25 crore, reflecting a payout ratio of 13.29% of standalone profits after tax. Dividends will be paid electronically within 30 days of the AGM, net of applicable TDS, to shareholders registered as of the record date, August 7, 2026.

Key AGM Agenda Items

The merger of KIA Health Tech Private Limited into Rubicon Research is designed to consolidate operations, reduce regulatory compliance costs, and optimize resource utilization. As KIA Health Tech is a wholly-owned subsidiary, no shares will be issued or consideration paid in the transaction. The merger is expected to enhance cash management efficiency and streamline the company’s manufacturing footprint without altering the shareholding pattern or voting rights of existing shareholders.

New ESOP Scheme and Governance Updates

Shareholders will vote on the Rubicon Research Limited Stock Options Plan 2026 (ESOP 2026), which creates an aggregate pool of 24,84,415 employee stock options. This includes 18,12,253 fresh options and 6,72,162 unutilized options carried forward from the previous scheme. The plan aims to attract and retain talent by aligning employee interests with long-term shareholder value. Additionally, the AGM will approve the remuneration framework for non-executive independent directors for a three-year period commencing October 1, 2026, aligning their compensation with market benchmarks and increased governance responsibilities.

Tax Compliance and Voting Process

To claim exemptions or lower TDS rates on the dividend, resident individuals must update their Permanent Account Number (PAN) and tax residential status with their Depository Participants (CDSL or NSDL) by August 10, 2026. Non-resident shareholders must submit a Tax Residency Certificate (TRC) and Form 41 to avail benefits under Double Taxation Avoidance Agreements (DTAA). Failure to provide these documents may result in higher TDS deductions at 20% plus surcharge and cess. Remote e-voting for the AGM begins on August 22, 2026, and ends on August 25, 2026, with voting rights determined based on holdings as of the cut-off date, August 19, 2026.

What the Numbers Show

The proposed dividend increase signals management’s confidence in the company’s cash generation capabilities following its IPO in October 2025. With revenue from operations growing 37% year-on-year to ₹17,540 million in FY26 and profit after tax surging 84% to ₹2,467 million, the company has strengthened its balance sheet significantly. The move to merge KIA Health Tech further indicates a strategic focus on operational efficiency and cost reduction, potentially improving future margins as the company integrates its supply chain and reduces administrative overheads.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE506V01022/dc586611-55ea-49e9-a8fb-ceffc523e26d.pdf

Rubicon Research Ltd has filed the Scheme of Amalgamation to merge its wholly owned subsidiary, Kia Health Tech Private Limited, with itself under Section 233 of the Companies Act, 2013. The appointed date for the merger is April 1, 2026. As the transferor company is a wholly owned subsidiary, no shares will be issued, and no consideration will be payable, resulting in no change to the shareholding pattern or voting rights of the company. The scheme is subject to statutory, regulatory, shareholder, and creditor approvals.

The Board of Directors approved the scheme at a meeting held on July 20, 2026. The merger aims to achieve business synergy, pool resources, and optimise existing capabilities into a single entity. It is expected to result in economies of scale, reduction in overheads, and better utilisation of financial and human resources. The amalgamation will also reduce multiplicity of legal and regulatory compliances and augment the manufacturing footprint of Rubicon Research.

Key Corporate Actions

Capital Structure Changes

The authorised share capital of Rubicon Research will increase from ₹23,89,90,000 to ₹40,69,90,000 divided into 40,69,90,000 equity shares of Re. 1 each upon the merger of the authorised share capital of Kia Health Tech. The issued, subscribed, and paid-up share capital of the transferor company consists of 88,00,000 equity shares of ₹10 each, amounting to ₹880.00 lakh. The increase in the transferee company's issued capital as of June 30, 2026, was due to the exercise of employee stock options.

Merger Rationale

The proposed amalgamation is intended to facilitate the pooling of resources and exploit growth potential by combining activities under a single entity. It will enable better cash management and unfettered access to cash flow generated by the combined business. The merger will also help in rationalising vendors, aggregating purchase quantity, and managing the procurement supply chain more effectively. The scheme is conditional upon the approval of members and creditors, sanction by the Regional Director, and requisite consents from governmental authorities.